



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/00, C07K 14/435</b>		A1	(11) International Publication Number: <b>WO 96/23898</b>
			(43) International Publication Date: <b>8 August 1996 (08.08.96)</b>
(21) International Application Number: <b>PCT/DK96/00052</b>		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>31 January 1996 (31.01.96)</b>			
(30) Priority Data: 0110/95 31 January 1995 (31.01.95) DK 0982/95 7 September 1995 (07.09.95) DK			
(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): THASTRUP, Ole [DK/DK]; Birkevej 37, DK-3460 Birkerød (DK). TULLIN, Søren [DK/DK]; Solnavej 53, 1. tv., DK-2860 Søborg (DK). POULSEN, Lars, Kongsbak [DK/DK]; Vængestien 2A, DK-2840 Holte (DK). BJØRN, Sara, Petersen [DK/DK]; Klampenborgvej 102, DK-2800 Lyngby (DK).			
(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).			

## (54) Title: A METHOD OF DETECTING BIOLOGICALLY ACTIVE SUBSTANCES

## (57) Abstract

The present invention relates to a method of detecting a biologically active substance affecting intracellular processes, the method comprising: (a) culturing a cell containing a DNA sequence coding for (i) a green fluorescent protein (GFP) having a protein kinase recognition site, or (ii) a green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or (iii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and an enzyme recognition site or a binding domain for a second messenger under conditions permitting expression of the DNA sequence; (b) measuring the fluorescence of the cell; (c) incubating the cell with a sample suspected of containing a biologically active substance affecting intracellular processes; and (d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), such change being indicative of the presence of a biologically active substance in said sample.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## A METHOD OF DETECTING BIOLOGICALLY ACTIVE SUBSTANCES

### FIELD OF INVENTION

The present invention relates to a method of detecting biologically active substances affecting intracellular processes, and a DNA construct and a cell for use in the method.

### 5 BACKGROUND OF THE INVENTION

Second messengers and protein kinases play key roles in the signalling pathways that control the response of mammalian cells (and probably all eukaryotic cells) to most stimuli. Although such signalling pathways have been subjected to extensive studies, detailed knowledge on e.g. the exact timing and spatial characteristics of signalling 10 events is often difficult to obtain due to lack of a convenient technology. There is, however, one exception to this rule: our understanding of the role of  $\text{Ca}^{2+}$  in e.g. intracellular signalling has been greatly improved due to the development of the fluorescent  $\text{Ca}^{2+}$  probe FURA-2 that permits real times studies of  $\text{Ca}^{2+}$  in single living cells.

15 Moreover, the construction of probes for cAMP (Adams et al., *Nature* 349 (1991), 694-697) and activity of the cAMP-dependent protein kinase (Sala-Newby and Campbell, *FEBS* 307(2) (1992), 241-244) has been attempted. The protein kinase A probe, however, suffers from the drawback that it is based on the firefly luciferase and accordingly produces too little light for fast single cell measurements. The cAMP probe 20 on the other hand has to be microinjected and is therefore not well suited for routine laboratory work. In conclusion, both probes lack some of the elegant properties that resulted in the widespread use of FURA-2.

Recently it was discovered that Green Fluorescent Protein (GFP) expressed in many different cell types, including mammalian cells, became highly fluorescent (Chalfie et 25 al., *Science* 263 (1994), 802-805). WO/07463 describes a cell capable of expressing GFP

and a method for selecting cells expressing a protein of interest and GFP based on detection of GFP-fluorescence in the cells.

## SUMMARY OF THE INVENTION

The purpose of the present invention is to provide a method of detecting a biologically active substance affecting intracellular processes based on the use of green fluorescent protein, including wild-type GFP derived from the jelly fish *Aequorea victoria* and modifications of GFP, such as modifications that changes the spectral properties of the GFP fluorescence, for the construction of probes, preferably real time probes for second messengers and protein kinase activity.

10 In one aspect, the present invention relates to a DNA construct comprising a DNA sequence coding for

- (i) green fluorescent protein (GFP) wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or
- 15 (ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site.

In another aspect, the present invention relates to a cell containing a DNA sequence coding for

- (i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or
- 20

(ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site, and capable of expressing said DNA sequence.

In a further aspect, the present invention relates to a method of detecting a biologically active substance affecting intracellular processes, the method comprising

(a) culturing a cell containing a DNA sequence coding for

(i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or

10 (ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site

under conditions permitting expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

15 (c) incubating the cell with a sample suspected of containing a biologically active substance affecting intracellular processes, and

(d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), such change being indicative of the presence of a biologically active substance in said sample.

In a still further aspect, the present invention relates to a method of characterizing the 20 biological activity of a substance with biological activity, the method comprising

(a) culturing a cell containing a DNA sequence coding for

(i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or

5 (ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site

under conditions permitting expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

10 (c) incubating the cell with a sample of a biologically active substance affecting intracellular processes, and

(d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), said change being characteristic of the biological activity of the biologically active substance in said sample.

15 Furthermore, studies on the substrate specificity of the different protein kinase A (PKA) isoforms using synthetic peptides have shown that peptides containing the motifs **RRXSX** or **RXKRXXSX** (**S** being the phosphorylated amino acid) tend to be the best substrates for PKA, and a review by Zetterquist, Ö. et al. (in Kemp, B.E. (ed.) *Peptide and Protein Phosphorylation* (1990), 172-188, CRC Press, Boca Raton, Florida, USA)

20 confirms that most known substrates of PKA contain said motifs.

Available amino acid sequences of GFP do not suggest that GFP is a PKA substrate because of a lack of recognition sites comprising the motifs **RRXSX** or **RXKRXXSX**. It is therefore surprising that a native or wild-type green fluorescent protein (GFP) derived from the jellyfish *Aequorea victoria* can be phosphorylated by protein kinase A

and thereby the spectral properties of GFP are changed resulting in a substantial increase of fluorescence.

In a preferred aspect, the present invention relates to a method of detecting a biologically active substance affecting intracellular processes, the method comprising

5 (a) culturing a cell containing a DNA sequence coding for a wild-type green fluorescent protein having a protein kinase recognition site under conditions permitting expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

(c) incubating the cell with a sample suspected of containing a biologically active 10 substance affecting intracellular processes, and

(d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), such change being indicative of the presence of a biologically active substance in said sample.

In a further preferred aspect, the present invention relates to a method of 15 characterizing the biological activity of a substance with biological activity, the method comprising

(a) culturing a cell containing a DNA sequence coding for a wild-type green fluorescent protein having a protein kinase recognition site, under conditions permitting expression of the DNA sequence,

20 (b) measuring the fluorescence of the cell,

(c) incubating the cell with a sample of a biologically active substance affecting intracellular processes, and

(d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), said change being characteristic of the biological activity of the biologically active substance in said sample.

5 In a still further preferred aspect the present invention relates to a DNA construct comprising the DNA sequence shown in Fig. 4a coding for a wild-type GFP and a transformed cell containing said DNA construct and capable of expressing said DNA sequence. The transformed cell is preferably a mammalian cell. A microorganism, *E. coli* NN049087, carrying the DNA sequence shown in Fig. 4a has been deposited for 10 the purpose of patent procedure according to the Budapest Treaty in Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroderweg 1 b, D-38124 Braunschweig, Federal Republic of Germany, under the deposition No. DSM 10260.

In the present context, the term "green fluorescent protein" is intended to indicate a 15 protein which, when expressed by a cell, emits fluorescence (cf. Chalfie et al., *Science* 263, 1994, pp. 802-805). In the following, GFP in which one or more amino acids have been substituted, inserted or deleted is most often termed "modified GFP".

The term "second messenger" is used to indicate a low molecular weight component involved in the early events of intracellular signal transduction pathways.

20 The term "binding domain of a second messenger" is used to indicate a segment of a protein which, in the course of intracellular metabolic processes, binds the secondary messenger.

The term "enzyme recognition site" is intended to indicate a peptide sequence covalently modified by an enzyme (e.g. phosphorylated, glycosylated or cleaved), 25 preferably the enzyme recognition site is a protein kinase recognition site, which is intended to indicate a peptide sequence covalently modified by a kinase, i.e. phosphorylated.

It should be emphasized that phosphorylation of a protein at a protein kinase recognition site often is followed (or accompanied) by dephosphorylation of said protein. A GFP based probe for activity of given protein kinase(s) would therefore also provide information on the activity of relevant protein

5 phosphatases since the parameter monitored is the net phosphorylation of the GFP based probe.

The term "hybrid polypeptide" is intended to indicate a polypeptide which is a fusion of at least a portion of each of two proteins, in this case at least a portion of the green fluorescent protein and at least a portion of a binding domain of a second messenger 10 or an enzyme recognition site.

In the present context, the term "biologically active substance" is intended to indicate a substance which has a biological function or exerts a biological effect in the human or animal body. The sample may be a sample of a biological material such as a microbial extract, or it may be a sample containing a compound or mixture of 15 compounds prepared by organic synthesis.

The phrase "any change in fluorescence" means any change in absorption properties, such as wavelength and intensity, or any change in spectral properties of the emitted light, such as a change of wavelength, fluorescence lifetime, intensity or polarisation.

The mechanism(s) behind a change in e.g. the fluorescence intensity of a 20 modified GFP upon phosphorylation could be several. As one possibility, phosphorylation of said GFP variant could change the chromophore environment, either due to proximity of the added phosphate group or to phosphorylation induced conformational changes. Correspondingly, binding of e.g. a second messenger to the binding domain of a some GFP variant or GFP fusion protein 25 could induce conformational changes that ultimately changes the chromophore environment and thereby the fluorescence. As support for these suggestions, it has been shown that amino acid substitutions distant to the chromophore (e.g. amino acids 167, 202, 203 and 222) can change the fluorescence intensity and

spectral characteristics of GFP (Ehrig et al. (1995) FEBS Letters 367:163; Heim et al. (1994) Proc. Natl. Acad. Sci. 91:12501).

The development of luminescent probes according to the present invention allows real 5 time studies of second messengers and specific enzymes such as protein kinases in single living cells, thereby making it possible to study the precise timing and the spatial characteristics of these factors. Moreover, studies on heterogeneity in cell populations are made possible.

Due to the strong fluorescence of GFP, the luminescence of cells expressing the probes 10 may easily be detected and analyzed by employing a combination of fluorescence microscopy and image analysis. Furthermore, it should be emphasized that the probes described are easy to introduce into cells, as they can be expressed in the cells of interest after transfection with a suitable expression vector.

Real time recombinant probes for second messengers and enzyme activity, such as 15 kinase activity, are not only useful in basic research but also in screening programmes aiming at identifying novel biologically active substances. Many currently used screening programmes designed to find compounds that affect cAMP concentration and protein kinase activity are based on receptor binding and/or reporter gene expression. The recombinant probes described herein, on the other hand, make it possible to develop 20 an entirely new type of screening assays able to monitor immediate and transient changes of cAMP concentration and protein kinase activity in intact living cells.

Any novel feature or combination of features described herein is considered essential to this invention.

#### DETAILED DESCRIPTION OF THE INVENTION

25 In a preferred embodiment of the present invention, the gene encoding GFP is derived from the jellyfish *Aequorea victoria*. The sequence of this gene is described in Prasher et al., Gene 111, 1992, pp. 229-233 (GenBank Accession No. M62653). The gene may

be modified so as to code for a variant GFP in which one or more amino acid residues have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site. According to this embodiment, it is preferred to insert a DNA sequence coding for an enzyme recognition site into the gene coding 5 for GFP, for instance at one of the following positions: between amino acid 39 and 40, between amino acid 71 and 72, between amino acid 79 and 80, between amino acid 107 and 108, between amino acid 129 and 130, between amino acid 164 and 165, or between amino acid 214 and 215. Points of insertion may be selected on the basis of surface probability (which may be calculated using the GCG software package which 10 employs a formula of Emini et al., *J. Virol.* 55(3), 1985, pp. 836-839). When the enzyme is protein kinase C, the recognition site inserted should preferably contain the motif **XRXXSXRX**, S being the phosphorylated amino acid. In successful constructs of this type, phosphorylation of the modified GFP may result in detectably altered optical properties of GFP. It should be noted that extensive deletion may result in loss of the 15 fluorescent properties of GFP. It has been shown, that only one residue can be sacrificed from the amino terminus and less than 10 or 15 from the carboxyl terminus before fluorescence is lost, cf. Cubitt et al. *TIBS* Vol. 20 (11), pp. 448-456, November 1995. Thus, according to this invention the modification of the GFP gene so as to code 20 for a variant GFP in which one or more amino acid residues have been substituted, inserted or deleted is limited to modifications resulting in a variant GFP having fluorescence properties.

The binding domain of a second messenger may be a receptor of a second messenger. The second messenger may be cyclic AMP, inositol phosphate 3, cyclic GMP, cyclic 25 ADP or diacylglycerol. The binding domain is preferably the cyclic AMP receptor (CRP, e.g. as described in Weber and Steitz, *J. Mol. Biol.* 198, 1987, pp. 311-326; Schroeder and Dobrogosz, *J. Bacteriol.* 167, 1986, pp. 612-622) or a part thereof capable of binding cyclic AMP.

Native CRP has two distinct domains: an N-terminal cAMP binding domain as well as a C-terminal DNA binding activity (Weber and Steitz, *J. Mol. Biol.* 198 (1987), 311-30 326). Upon binding of cAMP to the N-terminal portion of CRP a conformational

change is induced in the C-terminus, which allows the binding of CRP to the promoters of certain genes. In the successful fusions of CRP (or a portion thereof) to GFP (or a portion thereof), cAMP induced conformational changes in CRP are transmitted to GFP, thereby changing the optical properties of GFP.

5 In a preferred embodiment of the present invention, the gene or cDNA sequence encoding a wild-type GFP is derived from the jellyfish *Aequorea victoria*. A preferred sequence of this gene is disclosed by Fig. 4a herein. Fig. 4a shows the nucleotide sequence of a wild-type GFP (Hind3-EcoR1 fragment) and Fig. 4b shows the amino acid sequence, wherein start codon ATG corresponds to position 8 and stop codon 10 TAA corresponds to position 722 in the nucleotide sequence of Fig. 4a. Another sequence of an isotype of this gene is disclosed by Prasher et al., Gene 111, 1992, pp. 229-233 (GenBank Accession No. M62653). Any gene that codes for a fluorescent protein, such as wild-type GFP, having a protein kinase recognition site, and derived from any organism expressing a green fluorescent protein or similar fluorescent, 15 phosphorescent or luminescent protein may be used in this invention.

The enzyme recognition site or protein kinase recognition site is preferably a Ser/Thr or Tyr protein kinase, such as protein kinase C or a protein kinase A recognition site (both are reviewed in e.g. B.E. Kemp and R.B. Pearson, TIBS 15, Sept. 1990, pp. 342-346), or the insulin receptor or the Src kinase or a portion thereof containing a motif 20 required as a substrate for protein kinase, as suggested above. Kinase catalysed phosphorylation may result in detectably altered optical properties of GFP.

The DNA sequence encoding GFP, the binding domain of a second messenger or the enzyme recognition site may suitably be of genomic or cDNA origin, for instance obtained by preparing a suitable genomic or cDNA library and screening for DNA 25 sequences coding for all or part of any of these proteins by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., supra).

The DNA construct of the invention encoding the wild-type GFP, modified GFP or hybrid polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phosphoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors. For most purposes, it may be practical to prepare a shorter DNA sequence such as the DNA sequence coding for the enzyme recognition site synthetically, while the DNA coding for GFP or the binding domain of a second messenger will typically be isolated by screening of a DNA library.

Furthermore, the DNA construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire DNA construct, in accordance with standard techniques (cf. Sambrook et al., Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory, New York, USA).

The DNA construct may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491. A more recent review of PCR methods may be found in PCR Protocols, 1990, Academic Press, San Diego, California, USA.

The DNA sequence coding for GFP may also be modified by other means such as by conventional chemical mutagenesis or by insertion, deletion or substitution of one or more nucleotides in the sequence, either as random or site-directed mutagenesis. It is expected that such mutants will exhibit altered optical properties or altered heat stability.

The DNA construct of the invention may be inserted into a recombinant vector which may be any vector which may conveniently be subjected to recombinant DNA procedures. The choice of vector will often depend on the host cell into which it is to

be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated 5 together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding wild-type GFP, the modified GFP or the hybrid polypeptide is operably linked to additional segments required for transcription of the DNA. In general, the expression vector is derived from plasmid or viral DNA, or may contain elements of both. The 10 term, "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence coding for the modified GFP or hybrid polypeptide

The promoter may be any DNA sequence which shows transcriptional activity in the 15 host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the DNA sequence encoding wild-type GFP, the modified GFP or hybrid polypeptide in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell Biol. 1 (1981), 854 -864), the MT-1 20 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809 - 814) or the adenovirus 2 major late promoter.

An example of a suitable promoter for use in insect cells is the polyhedrin promoter (US 4,745,051; Vasuvedan et al., FEBS Lett. 311, (1992) 7 - 11), the P10 promoter (J.M. Vlak et al., J. Gen. Virology 69, 1988, pp. 765-776), the *Autographa californica* 25 polyhedrosis virus basic protein promoter (EP 397 485), the baculovirus immediate early gene 1 promoter (US 5,155,037; US 5,162,222), or the baculovirus 39K delayed-early gene promoter (US 5,155,037; US 5,162,222).

Examples of suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. **255** (1980), 12073 - 12080; Alber and Kawasaki, J. Mol. Appl. Gen. **1** (1982), 419 - 434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al., Nature **304** (1983), 652 - 654) promoters.

Examples of suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. **4** (1985), 2093 - 2099) or the tpiA promoter. Examples of other useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral  $\alpha$ -amylase, *A. niger* acid stable  $\alpha$ -amylase, *A. niger* or *A. awamori* glucoamylase (gluA), *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase. Preferred are the TAKA-amylase and gluA promoters.

15 Examples of suitable promoters for use in bacterial host cells include the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus licheniformis* alpha-amylase gene, the *Bacillus amyloliquefaciens* BAN amylase gene, the *Bacillus subtilis* alkaline protease gen, or the *Bacillus pumilus* xylosidase gene, or by the phage Lambda  $P_R$  or  $P_L$  promoters or the *E. coli* lac, trp or tac promoters.

20 The DNA sequence encoding wild-type GFP, the modified GFP or hybrid polypeptide of the invention may also, if necessary, be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) or (for fungal hosts) the TPI1 (Alber and Kawasaki, op. cit.) or ADH3 (McKnight et al., op. cit.) terminators. The vector may further comprise elements such as polyadenylation signals 25 (e.g. from SV40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).

The recombinant vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. An example of such a sequence (when the host cell is a mammalian cell) is the SV40 origin of replication.

When the host cell is a yeast cell, suitable sequences enabling the vector to replicate 5 are the yeast plasmid  $2\mu$  replication genes REP 1-3 and origin of replication.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or the *Schizosaccharomyces pombe* TPI gene (described by P.R. Russell, Gene 40, 1985, pp. 125-130), or one which confers resistance to a drug, e.g. 10 ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin or hygromycin. For filamentous fungi, selectable markers include amdS, pyrG, argB, niaD, sC.

The procedures used to ligate the DNA sequences coding for wild-type GFP, the modified GFP or hybrid polypeptide, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors 15 containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

The host cell into which the DNA construct or the recombinant vector of the invention is introduced may be any cell which is capable of expressing the present DNA construct and includes bacteria, yeast, fungi and higher eukaryotic cells, such as mammalian cells.

20 Examples of bacterial host cells which, on cultivation, are capable of expressing the DNA construct of the invention are grampositive bacteria such as strains of *Bacillus*, such as strains of *B. subtilis*, *B. licheniformis*, *B. lenthus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. laetus*, *B. megatherium* or *B. thuringiensis*, or strains of *Streptomyces*, such as *S. lividans* or *S. murinus*, or 25 gramnegative bacteria such as *Escherichia coli*. The transformation of the bacteria may be effected by protoplast transformation or by using competent cells in a manner known per se (cf. Sambrook et al., supra).

Examples of suitable mammalian cell lines are the HEK293 and the HeLa cell lines, primary cells, and the COS (e.g. ATCC CRL 1650), BHK (e.g. ATCC CRL 1632, ATCC CCL 10), CHL (e.g. ATCC CCL39) or CHO (e.g. ATCC CCL 61) cell lines. Methods of transfecting mammalian cells and expressing DNA sequences introduced 5 in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. **159** (1982), 601 - 621; Southern and Berg, J. Mol. Appl. Genet. **1** (1982), 327 - 341; Loyter et al., Proc. Natl. Acad. Sci. USA **79** (1982), 422 - 426; Wigler et al., Cell **14** (1978), 725; Corsaro and Pearson, Somatic Cell Genetics **7** (1981), 603, Graham and van der Eb, Virology **52** (1973), 456; and Neumann et al., EMBO J. **1** (1982), 841 - 845.

10 Examples of suitable yeasts cells include cells of *Saccharomyces* spp. or *Schizosaccharomyces* spp., in particular strains of *Saccharomyces cerevisiae* or *Saccharomyces kluyveri*. Methods for transforming yeast cells with heterologous DNA and producing heterologous polypeptides therefrom are described, e.g. in US 4,599,311, US 4,931,373, US 4,870,008, 5,037,743, and US 4,845,075, all of which are hereby 15 incorporated by reference. Transformed cells are selected by a phenotype determined by a selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient, e.g. leucine. A preferred vector for use in yeast is the POT1 vector disclosed in US 4,931,373. The DNA sequence encoding the modified GFP or hybrid polypeptide may be preceded by a signal sequence and optionally a leader 20 sequence, e.g. as described above. Further examples of suitable yeast cells are strains of *Kluyveromyces*, such as *K. lactis*, *Hansenula*, e.g. *H. polymorpha*, or *Pichia*, e.g. *P. pastoris* (cf. Gleeson et al., J. Gen. Microbiol. **132**, 1986, pp. 3459-3465; US 4,882,279).

Examples of other fungal cells are cells of filamentous fungi, e.g. *Aspergillus* spp., *Neurospora* spp., *Fusarium* spp. or *Trichoderma* spp., in particular strains of *A. oryzae*, 25 *A. nidulans* or *A. niger*. The use of *Aspergillus* spp. for the expression of proteins is described in, e.g., EP 272 277, EP 230 023, EP 184 438.

When a filamentous fungus is used as the host cell, it may be transformed with the DNA construct of the invention, conveniently by integrating the DNA construct in the host chromosome to obtain a recombinant host cell. This integration is generally con-

sidered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous or heterologous recombination.

5 Transformation of insect cells and production of heterologous polypeptides therein may be performed as described in US 4,745,051; US 4,879,236; US 5,155,037; 5,162,222; EP 397,485) all of which are incorporated herein by reference. The insect cell line used as the host may suitably be a *Lepidoptera* cell line, such as *Spodoptera frugiperda* cells or *Trichoplusia ni* cells (cf. US 5,077,214). Culture conditions may suitably be as described 10 in, for instance, WO 89/01029 or WO 89/01028, or any of the aforementioned references.

The transformed or transfected host cell described above is then cultured in a suitable nutrient medium under conditions permitting the expression of the present DNA construct after which the cells may be used in the screening method of the invention. 15 Alternatively, the cells may be disrupted after which cell extracts and/or supernatants may be analysed for fluorescence.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be 20 prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).

In the method of the invention, the fluorescence of cells transformed or transfected with the DNA construct of the invention may suitably be measured in a spectrometer where the spectral properties of the cells in liquid culture may be determined as scans 25 of light excitation and emission. Alternatively, such cells grown on nitrocellulose filters placed on plates containing solid media may be illuminated with a scanning polychromatic light source and imaged with an integrating colour camera. The colour

of the emitted light may then be determined by image analysis using specialised software.

The invention is further illustrated in the following examples with reference to the appended drawings, wherein

5 Fig. 1 shows a map of the pUC19-GFP plasmid construction. GFP nucleotide numbers referred to below with a "G" are from the GenBank GFP sequence record (accession No. M62653). Bases in italics represent GFP sequence. The pUC19 nucleotide numbers referred to below with a "P" are from the GenBank pUC19 sequence record (accession No. X02514). Bases in plain text represent pUC19 sequence. Bases in bold represent 10 non-GFP non-pUC19 sequence, which have been inserted by PCR for the introduction convenient restriction sites.

Fig. 2 shows maps of the four basic GFP-CRP fusion constructs:

- A) Full length GFP at the N-terminal fused with full length CRP at the C-terminal.
- B) Truncated GFP at the N-terminal fused with full length CRP at the C-terminal.
- 15 C) Full length CRP at the N-terminal fused with full length GFP at the C-terminal.
- D) Truncated CRP at the N-terminal fused with full length GFP at the C-terminal, corresponding to the construct where the DNA binding domain of CRP has been replaced with GFP.

GFP nucleotide numbers referred to below with a "G" are from the GenBank GFP 20 sequence record (accession No. M62653). CRP nucleotide numbers referred to below with a "C" are from the GenBank CRP sequence record (accession No. M13770). The pUC19 nucleotide numbers referred to below with a "P" are from the GenBank pUC19 sequence record (accession No. X02514).

### Example 1

#### 25 Cloning of cDNA encoding the green fluorescent protein

Briefly, total RNA, isolated from *A. victoria* by a standard procedure (Sambrook et al., Molecular Cloning. 2., eds. (1989) (Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York), 7.19-7.22) was converted into cDNA by using the AMV reverse transcriptase (Promega, Madison, WI, USA) as recommended by the manufacturer.

5 The cDNA was then PCR amplified, using PCR primers designed on the basis of a previously published GFP sequence (Prasher et al., Gene 111 (1992), 229-233; GenBank accession No. M62653) together with the *U*ITma™ polymerase (Perkin Elmer, Foster City, CA, USA). The sequences of the primers were: GFP2: **TGGAATAAGCTTATGAGTAAAGGAGAAGAACTTT** and GFP-1:

10 **AAGAATTCTGGATCCCTTACTGTCAATTGGAAGTCT**

Restriction endonuclease sites inserted in the 5' (a HindIII site) and 3' (EcoRI and BamHI sites) primers facilitated the cloning of the PCR amplified GFP cDNA into a slightly modified pUC19 vector. The details of the construction are as follows: LacZ Shine-Dalgarno AGGA, immediately followed by the 5' HindIII site plus an extra T and 15 the GFP ATG codon, giving the following DNA sequence at the lacZ-promoter GFP fusion point: *P*<sub>lacZ</sub>-AGGAAAGCTTATG-GFP. At the 3' end of the GFP cDNA, the base pair corresponding to nucleotide 770 in the published GFP sequence (GenBank accession No. M62653) was fused to the EcoRI site of the pUC19 multiple cloning site (MCS) through a PCR generated BamHI, EcoRI linker region.

20 Example 2

#### Isolation of mutant GFPs

A variant of GFP with altered optical properties and/or heat stability is prepared by subjecting the GFP described in Example 1 to a round of chemical mutagenesis followed by screening potential mutants for altered properties.

25 In brief, the GFP-encoding DNA sequence described in Example 1 (the HindIII-EcoRI fragment) is heat-denatured and subjected to chemical mutagens essentially as described by Myer et al., Science 229, 1985, p. 242. The mutagen is either nitrous acid, or permanganate or formic acid. The resulting mutated population of single stranded

GFP fragments are either amplified by PCR using the primers described in Example 1, or reverse transcribed by AMV reverse transcriptase as described in Example 1 prior to amplification by PCR. The PCR products are cleaved by restriction enzymes HindIII and EcoRI and the products of this reaction are ligated into the modified pUC19 5 plasmid described in Example 1.

The ligation reaction is transformed into an *E. coli* strain and plated on LB agar plates containing 100 µg/ml ampicillin to give approximately 500 transformants per plate. The fluorescence of GFP in the cells is detected by exciting the plates with a light source at 398 nm or 365 nm. Replicas of colonies are made onto fresh plates or plates on 10 which a nitrocellulose filter has been placed prior to replication. When colonies have formed once more, they are individually collected and resuspended in water. The cell suspensions are placed in a LS50B Luminescence Spectrometer (Perkin Elmer Ltd., Beaconsfield, Buckinghamshire, England) equipped with a temperature-controlled cuvet holder, and the spectral properties (scans of both light excitation and emission) are 15 determined. Alternatively, whole plates with approximately 500 transformants are illuminated with a scanning polychromatic light source (fast monochromator from T.I.L.L. Photonics, Munich, Germany) and imaged with an integrating RGB colour camera (Photonic Science Color Cool View). The actual colour of the emitted light was determined by image analysis using the Spec R4 software (Signal Analytics Corporation, 20 Vienna, VA, USA).

Heat sensitivity of the mutated GFP is tested by characterizing its spectral properties, as described above, after a sequential rise of the temperature from 20°C to 80°C.

In another round of mutagenesis, *E.coli* cells containing the GFP pUC19 plasmid described in Example 1, are subjected to treatment with N-methyl-N-nitro-N-25 nitrosoguanidine at a concentration of 25 milligrams per liter for 18 hours, and the cells are plated and analyzed as described above. Alternatively, plasmids are first recovered from the treated cells and transformed into *E.coli* and plated and analyzed as described above.

Example 3Construction of a GFP-based recombinant cAMP probe

The basis of the GFP-based recombinant cAMP probe described herein is the fusion of a portion of the cAMP receptor protein (CRP) from *E. coli* to GFP.

5 It was decided to prepare 4 basic GFP-CRP fusion constructs, from which a whole array of semi-random fusion constructs may be generated, some of which are expected to have the ability to induce conformational changes in GFP when cAMP is bound to the N-terminal portion of CRP resulting in detectable changes in the optical properties of GFP.

**10 1. Description of the four basic GFP-CRP fusions**

The plasmid harbouring the GFP-CRP fusion shown in figure 2 A) was constructed the following way: The CRP insert of plasmid pH A7 (Aiba et al., Nucl. acids Res. 10 (1982) 1345-1377) was PCR amplified with the PCR primers

CRP1 (CGATACAGATCTAAGCTTATGGTGCTTGGCAAACCGC) and

15 CRP-2 (CGGAATTCTAAAAGCTTAGATCTTACCGTGTGCGGAGATCAG) followed by digestion with the restriction endonucleases BglII and EcoRI. The GFP insert of plasmid pUC19-GFP (see Example 1) was PCR amplified using the PCR primers GFP2 (see Example 1) and

GFP-4 (GAATCGTAGATCTTGTATAGTTCATCCATGCCATG) followed by

20 digestion with the restriction endonucleases HindIII and BglII. Subsequently, in a three-part ligation, the BglII/EcoRI fragment of the PCR amplified CRP DNA and the HindIII/BglII fragment of the PCR amplified GFP DNA was ligated with a HindIII/EcoRI vector fragment of the slightly modified pUC19 plasmid described in Example 1, followed by transformation of *E. coli*.

The plasmid harbouring the GFP-CRP fusion shown in figure 2 B) was constructed essentially as described above for the figure 2 A) plasmid with a single modification:

The PCR primer

15 GFP-3 (GAATCGTAGATCTTGACTTCAGCACGTGTCTTGT) was used instead of the GFP-4 PCR primer.

The plasmid harbouring the CRP-GFP fusion shown in figure 2 C) was made by PCR amplification of the CRP insert of plasmid pH A7 with PCR primers CRP1 and CRP-2, followed by digestion with restriction endonuclease HindIII and ligation into the HindIII site of plasmid pUC19-GFP (see Example 1).

10 The plasmid harbouring the GFP-CRP fusion shown in figure 2 D) was constructed essentially as described above for the figure 2 C) plasmid with a single modification:

The PCR primer

15 GFP-1 (CCAGTTAAGCTTAGATCTTCCGGGTGAGTCATAGCGTCTGG) was used instead of the CRP-2 PCR primer.

### 15 2. *Generation of semirandom GFP-CRP fusions*

The 4 basic GFP-CRP fusion plasmids described above are digested with the restriction endonuclease BglII (opening the plasmids at GFP-CRP fusion points), followed by treatment with the double stranded exonuclease Bal31 for 1 minute, 2 minutes, 3 minutes etc. up to 20 minutes (cf. Sambrook et al., op. cit. at 15.24). Subsequently, the

20 Bal31 treated DNA is incubated with the T4 DNA polymerase (cf. Sambrook et al., op. cit. at 15.24) to generate blunt ends, followed by self ligation (essentially as described by Sambrook et al., op. cit. at 1.68). Finally, the self ligated Bal31 treated plasmid DNA is transformed into *E. coli*.

#### 3a. *Screening of the CRP-GFP fusions for cAMP induced changes in fluorescence*

25 *E. coli* transformants expressing one of the four basic CRP-GFP fusions or one of the semirandom GFP-CRP fusions are grown overnight in 2 ml Luria-Bertani medium with

added ampicillin (100 µg/ml). The cells are then pelleted by centrifugation followed by resuspension in 0.5 ml lysis buffer (100 mM NaCl, 1 mM EDTA and 50 mM Tris pH 8.0). Subsequently, 25 µl 10 mg/ml Lysozyme is added to the resuspended cells, followed by incubation for 10 min. at room temperature, vigorous vortexing and 5 centrifugation for 5 min. at 20 000 x g. Finally, emission and excitation spectra for the resulting protein extracts (the supernatants) are acquired by using the LS50B Luminescence Spectrometer and the FL Data Manager software package (both from Perkin Elmer Ltd., Beaconsfield, Buckinghamshire, England). The spectra recorded before as well as after the addition of cAMP to a final concentration of 0.5 mM are 10 compared by using the Graph Builder software package (Perkin Elmer). The CRP-GFP fusions exhibiting cAMP induced changes in fluorescence are investigated further by expression in mammalian cells.

*3b. (alternative protocol) Screening of the CRP-GFP fusions for cAMP induced changes in fluorescence.*

15 Cyclic AMP levels in E.coli cells vary according to the carbon source provided; see e.g. Epstein et.al. (1975), Proc.Natl.Acad.Sci.USA 72, pp. 2300-2304, and Botsford and Harman (1992), Microbiological Reviews 56, p. 100-122. For example, cells grown on glucose contain a lower level of cAMP than cells grown on e.g. glycerol. Furthermore, shifting cells from one carbon source to another, or adding glucose to a culture grown 20 on a non-glucose carbon source change the cAMP level of the cells. Hence, the cAMP-induced change in the fluorescence of the CRP-GFP fusions may be determined by continuously measuring the fluorescence of cells expressing the fusions, after transfer from medium containing e.g. glycerol as carbon to medium containing 0.2% glucose. The cells are analyzed in liquid culture in the LS50B Luminescence Spectrometer or 25 by growing them on nitrocellulose filters placed on plates with solid media; the filter is transferred from plates with one type of medium to plates with another type of medium, and the fluorescence is continuously monitored by exciting the plates with a scanning polychromatic light source (fast monochromator from T.I.L.L. Photonics, Munnich, Germany) and collecting colour images with an integrating RGB color 30 camera (Photonic Science Color Cool View). The actual colour of the emitted light is

determined by image analysis using the Spec R4 software package (Signal Analytics Corporation, Vienna, VA, USA).

#### Example 4

##### Construction of a GFP based recombinant probe for protein kinase activity

##### *5 Description of the GFP based recombinant protein kinase C (PKC) substrates*

Studies on the substrate specificity of the different PKC isoforms using synthetic peptides have shown that peptides containing the motif **XRXXSXRX** (S being the phosphorylated amino acid) tend to be the best substrates for PKC (as reviewed in Kemp, B. E. and Pearson, R. B. (1990) *TIBS* 15 Sept., 342-346). Moreover, the 10 naturally occurring neuronal PKC substrate GAP-43 has the following amino acid sequence around the phosphorylated serine residue (underlined): **AATKIQASFRGHIT** (Kosik, K.S et al. (1988) *Neuron* 1, 127-132). On the basis of these data we have selected the putative PKC recognition motif **RQASFRS** for insertion in GFP at various positions. Insertion points were selected on the basis of surface probability (calculated 15 using the GCG software package, which employs a formula of Emini et al.(1985) *J. Virol.*, 55(3), 836-839 ), slightly modified for the end values of the protein chains. The single probabilities are taken from Janin et al. (1978) *J. Mol. Biol.* 125, 357-386) and/or vicinity of the GFP chromophore. The heptapeptide is inserted in GFP by PCR at the following positions:

20 Between amino acid (aa) 39 and aa 40 (PCR primers PKC-1: **GATACCAAAGATCTGAAAGAAGCTTGTCCGTATGTTGCATCACCTTCACC** and  
PKC1: **GATACCAAAGATCTGGAAAACCTTACCCCTAAATT**),  
between aa 52 and aa 53 (PCR primers PKC-2:  
25 **GATACCAAAGATCTGAAAGAAGCTTGTCCGTTCAGTAGTGCAAATAAA** and  
PKC2: **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 71 and aa 72 (PCR primers PKC-3:  
30 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 83 and aa 84 (PCR primers PKC-4:  
35 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 94 and aa 95 (PCR primers PKC-5:  
40 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 106 and aa 107 (PCR primers PKC-6:  
45 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 118 and aa 119 (PCR primers PKC-7:  
50 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 130 and aa 131 (PCR primers PKC-8:  
55 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 142 and aa 143 (PCR primers PKC-9:  
60 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 154 and aa 155 (PCR primers PKC-10:  
65 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 166 and aa 167 (PCR primers PKC-11:  
70 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 178 and aa 179 (PCR primers PKC-12:  
75 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 190 and aa 191 (PCR primers PKC-13:  
80 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 202 and aa 203 (PCR primers PKC-14:  
85 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 214 and aa 215 (PCR primers PKC-15:  
90 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 226 and aa 227 (PCR primers PKC-16:  
95 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 238 and aa 239 (PCR primers PKC-17:  
100 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 250 and aa 251 (PCR primers PKC-18:  
105 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 262 and aa 263 (PCR primers PKC-19:  
110 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 274 and aa 275 (PCR primers PKC-20:  
115 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 286 and aa 287 (PCR primers PKC-21:  
120 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 298 and aa 299 (PCR primers PKC-22:  
125 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 310 and aa 311 (PCR primers PKC-23:  
130 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 322 and aa 323 (PCR primers PKC-24:  
135 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 334 and aa 335 (PCR primers PKC-25:  
140 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 346 and aa 347 (PCR primers PKC-26:  
145 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 358 and aa 359 (PCR primers PKC-27:  
150 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 370 and aa 371 (PCR primers PKC-28:  
155 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 382 and aa 383 (PCR primers PKC-29:  
160 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 394 and aa 395 (PCR primers PKC-30:  
165 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 406 and aa 407 (PCR primers PKC-31:  
170 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 418 and aa 419 (PCR primers PKC-32:  
175 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 430 and aa 431 (PCR primers PKC-33:  
180 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 442 and aa 443 (PCR primers PKC-34:  
185 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 454 and aa 455 (PCR primers PKC-35:  
190 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 466 and aa 467 (PCR primers PKC-36:  
195 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 478 and aa 479 (PCR primers PKC-37:  
200 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 490 and aa 491 (PCR primers PKC-38:  
205 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 502 and aa 503 (PCR primers PKC-39:  
210 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 514 and aa 515 (PCR primers PKC-40:  
215 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 526 and aa 527 (PCR primers PKC-41:  
220 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 538 and aa 539 (PCR primers PKC-42:  
225 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 550 and aa 551 (PCR primers PKC-43:  
230 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 562 and aa 563 (PCR primers PKC-44:  
235 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 574 and aa 575 (PCR primers PKC-45:  
240 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 586 and aa 587 (PCR primers PKC-46:  
245 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 598 and aa 599 (PCR primers PKC-47:  
250 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 610 and aa 611 (PCR primers PKC-48:  
255 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 622 and aa 623 (PCR primers PKC-49:  
260 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 634 and aa 635 (PCR primers PKC-50:  
265 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 646 and aa 647 (PCR primers PKC-51:  
270 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 658 and aa 659 (PCR primers PKC-52:  
275 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 670 and aa 671 (PCR primers PKC-53:  
280 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 682 and aa 683 (PCR primers PKC-54:  
285 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 694 and aa 695 (PCR primers PKC-55:  
290 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 706 and aa 707 (PCR primers PKC-56:  
295 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 718 and aa 719 (PCR primers PKC-57:  
300 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 730 and aa 731 (PCR primers PKC-58:  
305 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 742 and aa 743 (PCR primers PKC-59:  
310 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 754 and aa 755 (PCR primers PKC-60:  
315 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 766 and aa 767 (PCR primers PKC-61:  
320 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 778 and aa 779 (PCR primers PKC-62:  
325 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 790 and aa 791 (PCR primers PKC-63:  
330 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 802 and aa 803 (PCR primers PKC-64:  
335 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 814 and aa 815 (PCR primers PKC-65:  
340 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 826 and aa 827 (PCR primers PKC-66:  
345 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 838 and aa 839 (PCR primers PKC-67:  
350 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 850 and aa 851 (PCR primers PKC-68:  
355 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 862 and aa 863 (PCR primers PKC-69:  
360 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 874 and aa 875 (PCR primers PKC-70:  
365 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 886 and aa 887 (PCR primers PKC-71:  
370 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 898 and aa 899 (PCR primers PKC-72:  
375 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 910 and aa 911 (PCR primers PKC-73:  
380 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 922 and aa 923 (PCR primers PKC-74:  
385 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 934 and aa 935 (PCR primers PKC-75:  
390 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 946 and aa 947 (PCR primers PKC-76:  
395 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 958 and aa 959 (PCR primers PKC-77:  
400 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 970 and aa 971 (PCR primers PKC-78:  
405 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 982 and aa 983 (PCR primers PKC-79:  
410 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 994 and aa 995 (PCR primers PKC-80:  
415 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1006 and aa 1007 (PCR primers PKC-81:  
420 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1018 and aa 1019 (PCR primers PKC-82:  
425 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1030 and aa 1031 (PCR primers PKC-83:  
430 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1042 and aa 1043 (PCR primers PKC-84:  
435 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1054 and aa 1055 (PCR primers PKC-85:  
440 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1066 and aa 1067 (PCR primers PKC-86:  
445 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1078 and aa 1079 (PCR primers PKC-87:  
450 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1090 and aa 1091 (PCR primers PKC-88:  
455 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1102 and aa 1103 (PCR primers PKC-89:  
460 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1114 and aa 1115 (PCR primers PKC-90:  
465 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1126 and aa 1127 (PCR primers PKC-91:  
470 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1138 and aa 1139 (PCR primers PKC-92:  
475 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1150 and aa 1151 (PCR primers PKC-93:  
480 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1162 and aa 1163 (PCR primers PKC-94:  
485 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1174 and aa 1175 (PCR primers PKC-95:  
490 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1186 and aa 1187 (PCR primers PKC-96:  
495 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1198 and aa 1199 (PCR primers PKC-97:  
500 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1210 and aa 1211 (PCR primers PKC-98:  
505 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1222 and aa 1223 (PCR primers PKC-99:  
510 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1234 and aa 1235 (PCR primers PKC-100:  
515 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1246 and aa 1247 (PCR primers PKC-101:  
520 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1258 and aa 1259 (PCR primers PKC-102:  
525 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1270 and aa 1271 (PCR primers PKC-103:  
530 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1282 and aa 1283 (PCR primers PKC-104:  
535 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1294 and aa 1295 (PCR primers PKC-105:  
540 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1306 and aa 1307 (PCR primers PKC-106:  
545 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1318 and aa 1319 (PCR primers PKC-107:  
550 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1330 and aa 1331 (PCR primers PKC-108:  
555 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1342 and aa 1343 (PCR primers PKC-109:  
560 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1354 and aa 1355 (PCR primers PKC-110:  
565 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1366 and aa 1367 (PCR primers PKC-111:  
570 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1378 and aa 1379 (PCR primers PKC-112:  
575 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1390 and aa 1391 (PCR primers PKC-113:  
580 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1402 and aa 1403 (PCR primers PKC-114:  
585 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1414 and aa 1415 (PCR primers PKC-115:  
590 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1426 and aa 1427 (PCR primers PKC-116:  
595 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1438 and aa 1439 (PCR primers PKC-117:  
600 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1450 and aa 1451 (PCR primers PKC-118:  
605 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1462 and aa 1463 (PCR primers PKC-119:  
610 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1474 and aa 1475 (PCR primers PKC-120:  
615 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1486 and aa 1487 (PCR primers PKC-121:  
620 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1498 and aa 1499 (PCR primers PKC-122:  
625 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1510 and aa 1511 (PCR primers PKC-123:  
630 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1522 and aa 1523 (PCR primers PKC-124:  
635 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1534 and aa 1535 (PCR primers PKC-125:  
640 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1546 and aa 1547 (PCR primers PKC-126:  
645 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1558 and aa 1559 (PCR primers PKC-127:  
650 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1570 and aa 1571 (PCR primers PKC-128:  
655 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1582 and aa 1583 (PCR primers PKC-129:  
660 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1594 and aa 1595 (PCR primers PKC-130:  
665 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1606 and aa 1607 (PCR primers PKC-131:  
670 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1618 and aa 1619 (PCR primers PKC-132:  
675 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1630 and aa 1631 (PCR primers PKC-133:  
680 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1642 and aa 1643 (PCR primers PKC-134:  
685 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1654 and aa 1655 (PCR primers PKC-135:  
690 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1666 and aa 1667 (PCR primers PKC-136:  
695 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1678 and aa 1679 (PCR primers PKC-137:  
700 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1690 and aa 1691 (PCR primers PKC-138:  
705 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1702 and aa 1703 (PCR primers PKC-139:  
710 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1714 and aa 1715 (PCR primers PKC-140:  
715 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1726 and aa 1727 (PCR primers PKC-141:  
720 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1738 and aa 1739 (PCR primers PKC-142:  
725 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1750 and aa 1751 (PCR primers PKC-143:  
730 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1762 and aa 1763 (PCR primers PKC-144:  
735 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1774 and aa 1775 (PCR primers PKC-145:  
740 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1786 and aa 1787 (PCR primers PKC-146:  
745 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1798 and aa 1799 (PCR primers PKC-147:  
750 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1810 and aa 1811 (PCR primers PKC-148:  
755 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1822 and aa 1823 (PCR primers PKC-149:  
760 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1834 and aa 1835 (PCR primers PKC-150:  
765 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1846 and aa 1847 (PCR primers PKC-151:  
770 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1858 and aa 1859 (PCR primers PKC-152:  
775 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1870 and aa 1871 (PCR primers PKC-153:  
780 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1882 and aa 1883 (PCR primers PKC-154:  
785 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1894 and aa 1895 (PCR primers PKC-155:  
790 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1906 and aa 1907 (PCR primers PKC-156:  
795 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1918 and aa 1919 (PCR primers PKC-157:  
800 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1930 and aa 1931 (PCR primers PKC-158:  
805 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1942 and aa 1943 (PCR primers PKC-159:  
810 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1954 and aa 1955 (PCR primers PKC-160:  
815 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1966 and aa 1967 (PCR primers PKC-161:  
820 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1978 and aa 1979 (PCR primers PKC-162:  
825 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 1990 and aa 1991 (PCR primers PKC-163:  
830 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2002 and aa 2003 (PCR primers PKC-164:  
835 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2014 and aa 2015 (PCR primers PKC-165:  
840 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2026 and aa 2027 (PCR primers PKC-166:  
845 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2038 and aa 2039 (PCR primers PKC-167:  
850 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2050 and aa 2051 (PCR primers PKC-168:  
855 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2062 and aa 2063 (PCR primers PKC-169:  
860 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2074 and aa 2075 (PCR primers PKC-170:  
865 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2086 and aa 2087 (PCR primers PKC-171:  
870 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2098 and aa 2099 (PCR primers PKC-172:  
875 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2110 and aa 2111 (PCR primers PKC-173:  
880 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2122 and aa 2123 (PCR primers PKC-174:  
885 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2134 and aa 2135 (PCR primers PKC-175:  
890 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2146 and aa 2147 (PCR primers PKC-176:  
895 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2158 and aa 2159 (PCR primers PKC-177:  
900 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2170 and aa 2171 (PCR primers PKC-178:  
905 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2182 and aa 2183 (PCR primers PKC-179:  
910 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2194 and aa 2195 (PCR primers PKC-180:  
915 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2206 and aa 2207 (PCR primers PKC-181:  
920 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2218 and aa 2219 (PCR primers PKC-182:  
925 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2230 and aa 2231 (PCR primers PKC-183:  
930 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2242 and aa 2243 (PCR primers PKC-184:  
935 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2254 and aa 2255 (PCR primers PKC-185:  
940 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2266 and aa 2267 (PCR primers PKC-186:  
945 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2278 and aa 2279 (PCR primers PKC-187:  
950 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2290 and aa 2291 (PCR primers PKC-188:  
955 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2302 and aa 2303 (PCR primers PKC-189:  
960 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2314 and aa 2315 (PCR primers PKC-190:  
965 **GATACCAAAGATCTCTACCTGTTCCATGGCCAACAC**),  
between aa 2326 and aa 2327 (PCR primers PKC-191:  
970 <

GATACCAAAGATCTGAAAGAAGCTTGTCAAAGCATTGAACACCATAAGA  
and

PKC3: GATACCAAAGATCTTCAAGATAACCCAGATCATATG),  
between aa 79 and 80 (PCR primers PKC-4:

5 GATACCAAAGATCTGAAAGAAGCTTGTGTTCATATGATCTGGGTATCT and  
PKC4: GATACCAAAGATCTCAGCATGACTTTCAAGAGT),

between aa 107 and 108 (PCR primers PKC-5:

GATACCAAAGATCTGAAAGAAGCTTGTGCGTTGTTAGTTCCCGTCATCTT and

PKC5: GATACCAAAGATCTACACGTGCTGAAGTCAAGTTT),

10 between aa 129 and 130 (PCR primers PKC-6:

GATACCAAAGATCTGAAAGAAGCTTGTGATCAATACCTTTAACTCGAT and

PKC6: GATACCAAAGATCTTTAAAGAAGATGGAAACATT),

between aa 164 and 165 (PCR primers PKC-7:

GATACCAAAGATCTGAAAGAAGCTTGTGGTTAACCTTGATTCCATTCTT and

15 PKC7: GATACCAAAGATCTTCAAAATTAGACACAACATT)

and between aa 214 and 215 (PCR primers PKC-8:

GATACCAAAGATCTGAAAGAAGCTTGTGCGTTTCGTTGGGATCTTCGA and

PKC8: GATACCAAAGATCTAGAGACCACATGGTCCTTCTT).

The PCR primers were designed in the following way: Reverse primers: 5'-

20 GATACCAA AGA TCT GAA AGA AGC TTG TCG-3' + 21 nucleotides of the  
antisense strand (upstream of the second aa mentioned) and forward primers: 5'-

GATACCAA AGA TCT-3' + 21 nucleotides of the sense strand (downstream of the

first aa), each PCR primer being provided with a unique BglII site (giving rise to the  
arginine and serine residues of the heptapeptide). The PKC site is inserted by PCR of

25 pUC19-GFP plasmid DNA (see Example 1) with the 8 forward primers and the 8  
matching reverse primers, followed by digestion with BglII, self-ligation and  
transformation of *E. coli* (cf. Sambrook et al., op. cit.).

**2. Screening of the GFP based recombinant PKC substrates for phosphorylation induced  
changes in fluorescence**

*E. coli* transformants expressing one of the eight GFP based recombinant PKC substrates are grown overnight in 2 ml Luria-Bertani medium with added ampicillin (100 µg/ml). The cells are then pelleted by centrifugation followed by resuspension in 0.5 ml lysis buffer (100 mM NaCl, 1 mM EDTA and 50 mM Tris pH 8.0). Subsequently, 25 5 µl 10 mg/ml Lysozyme is added to the resuspended cells, followed by incubation for 10 min. at room temperature, vigorous vortexing and centrifugation for 5 min. at 20 000 x g. Finally, emission and excitation spectra for the resulting protein extracts (the supernatants) are acquired by using the LS50B Luminescence Spectrometer and the FL Data Manager software package (Perkin Elmer). The spectra recorded before as well 10 as after treatment of the extracts with purified PKC (Promega, Madison, WI, USA) according to the manufacturers instruction, are compared by using the Graph Builder software package (Perkin Elmer). The GFP based recombinant PKC substrates exhibiting phosphorylation induced changes in fluorescence are investigated further by expression in mammalian cells.

### 15 Example 5

#### Characterization of the recombinant fusion probes in mammalian cells.

The CRP-GFP fusions (Example 3) exhibiting cAMP-induced changes in fluorescence as well as the GFP-based recombinant PKC substrates exhibiting phosphorylation-induced changes in fluorescence are investigated further by expression in mammalian 20 cells.

Inserts of the respective plasmids are isolated by digestion with the restriction endonucleases HindIII and BamHI and ligated into the HindIII and BamHI sites of the MCS of the mammalian pREP4 vector (Invitrogen, San Diego, California, USA). Subsequently, Baby Hamster Kidney (BHK) are transfected with the resulting plasmid 25 constructs according to the standard calcium phosphate-DNA precipitate protocol (cf. Sambrook et al., op. cit. at 16.33-16.35). Stable transfectants with high expression of the recombinant probes are identified and cloned after 6-14 days in culture by quantifying the fluorescence in an image analysis system, which consists of a Nikon Diaphot 200

microscope with a temperature controlled stage, a slow scan CCD camera (T.I.L.L. Photonics), a polychromatic light source (T.I.L.L. Photonics), and a PC based image analysis software package (FUCAL from T.I.L.L. Photonics). Alternatively, the fluorescence properties are monitored in a photometer based system. In this system the 5 CCD camera is replaced by a photomultiplier D104 (PTI, Canada).

The clones are cultured for a couple of days in glass coverslip chambers (NUNC, Copenhagen, Denmark) before image analysis.

The ability of the clones to detect changes in cAMP is characterized by elevating intracellular cAMP level by challenging the cells with forskolin (0.1-10  $\mu$ M) or dibutyryl-10 cAMP (1-100  $\mu$ M) and monitoring the associated change of spectral properties. Similarly, clones that are sensitive to variations in PKC activity are characterized by activating PKC in them with PMA (phorbol 12-myristate 13-acetate) (10-1000 nM) or OAG (1-oleoyl-2-acetyl-sn-glycerol) (1-100  $\mu$ M). The stimulant-induced changes of fluorescence properties are monitored continuously using above mentioned imaging 15 system. Combining imaging with photometry makes it possible to characterize the response of the recombinant probes in both high spatial and high temporal resolution.

#### Example 6

##### GFP as a recombinant probe for protein kinase activity

###### *Purification of GFP from *E. coli* cells expressing GFP*

20 *E. coli* cells containing a plasmid allowing expression of GFP were grown overnight at 24°C. Cells were pelleted, the supernatant was discarded, and the pellet was resuspended in 1/20 of the original volume in 100mM Na-phosphate buffer (pH 8.0). Cells were disrupted by sonication, and cell debris were pelleted at 12000g for 20 minutes. The supernatant was recovered, ammonium sulphate was added to a final 25 concentration of 1.5M, and the resulting solution was subjected to hydrophobic interaction chromatography by applying it to a Phenyl-Sepharose CL-4B column equilibrated with 1.5M ammonium sulphate. The column was eluted with water, and

fractions containing GFP were identified by green fluorescence when illuminated with 365nm UV light. To GFP containing fractions was added one volume of 20mM Tris, HCl (pH 7.5) and these were subjected to anion exchange chromatography by applying them to a Q-Sepharose column. The column was eluted with 20mM Tris, HCl (pH 7.5) 5 + 1.0M NaCl. GFP containing fractions were identified by green fluorescence when illuminated with 365nm UV light. GFP containing fractions were subjected to gelfiltration by applying them to a Superose-12 column equilibrated with 100mM Na-phosphate buffer (pH 8.0). The column was eluted with 100mM Na-phosphate buffer (pH 8.0) and fractions containing GFP were identified by green fluorescence when 10 illuminated with 365nm UV light. The resulting GFP preparation was greater than 95% pure as judged by HPLC analysis.

#### *In vitro GFP phosphorylation assay*

For *in vitro* phosphorylation of GFP, 0.5 $\mu$ g wild-type GFP (purified as described above) in 40mM Tris, pH 7.4, 20mM MgOAc and 0.2mM ATP (all from Sigma, St. Louis, MO, 15 USA) was incubated for 1-60 minutes at 37°C with 0-20 casein units of the catalytic subunit of the cAMP dependent protein kinase (Promega, Madison, WI, USA) and 0-200 $\mu$ M cAMP dependent protein kinase inhibitor. Emission (excitation wavelength 395nm or 470nm) and excitation (emission wavelength 508nm) spectra were acquired for all samples using the LS50B Luminescence Spectrometer and the FL data Manager 20 software package (Perkin Elmer). The spectra were subsequently compared by using the Graph Builder software package (Perkin Elmer).

As can be seen from Fig. 3, the fluorescence intensity of wild-type GFP increases approximately two-fold when incubated with the catalytic subunit of the cAMP dependent protein kinase. Moreover, 5 $\mu$ m cAMP dependent protein kinase inhibitor 25 inhibits the effect of the catalytic subunit of the cAMP dependent protein kinase.

Figure 3 shows emission spectra of 0.5 $\mu$ g wild-type GFP (purified as described in Example 6) in 40mM Tris, pH 7.4, 20mM MgOAc and 0.2mM ATP (all from Sigma), incubated for 5 minutes at 37°C with 10 casein units of the catalytic subunit of the

cAMP dependent protein kinase (Promega) with or without 5 $\mu$ M cAMP dependent protein kinase inhibitor (PKI). The control (w/o PKA) was incubated 5 minutes at 37°C without the catalytic subunit of the cAMP dependent protein kinase. The excitation wavelength was 395nm. RFI in the figure means relative fluorescence intensity.

### 5 Example 7

#### Characterization of wild-type GFP as a PKA activity probe in mammalian cells.

The green fluorescent proteins exhibiting phosphorylation-induced changes in fluorescence are investigated further by expression in mammalian cells.

Inserts of the respective plasmids are isolated by digestion with the restriction 10 endonucleases HindIII and BamHI and ligated into the HindIII and BamHI sites of the MCS of the mammalian pZEO-SV vector (Invitrogen, San Diego, California, USA). Subsequently, Baby Hamster Kidney (BHK) are transfected with the resulting plasmid constructs according to the standard calcium phosphate-DNA precipitate protocol (cf. 15 Sambrook et al., *op. cit.* at 16.33-16.35). Stable transfectants with high expression of the recombinant probes are identified and cloned after 6-14 days in culture by quantifying 20 the fluorescence in an image analysis system, which consists of a Nikon Diaphot 200 microscope with a temperature controlled stage, a slow scan CCD camera (T.I.L.L. Photonics), a polychromatic light source (T.I.L.L. Photonics), and a PC based image analysis software package (FUCAL from T.I.L.L. Photonics). Alternatively, the fluorescence properties are monitored in a photometer based system. In this system the 25 CCD camera is replaced by a photomultiplier D104 (PTI, Canada).

The clones are cultured for a couple of days in glass coverslip chambers (NUNC, Copenhagen, Denmark) before image analysis.

The ability of the clones to detect changes in protein kinase A activity is characterized 25 by elevating intracellular cAMP level by challenging the cells with forskolin (0.1-10  $\mu$ M) or dibutyryl-cAMP (1-100  $\mu$ M) and monitoring the associated change of spectral

properties. The stimulant-induced changes of fluorescence properties are monitored continuously using above mentioned imaging system. Combining imaging with photometry makes it possible to characterize the response of the recombinant probes in both high spatial and high temporal resolution.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM**  
 (PCT Rule 13bis)

**A.** The indications made below relate to the microorganism referred to in the description on page 6, line 12

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet

Name of depositary institution

DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL-KULTUREN GmbH

Address of depositary institution (including postal code and country)

Mascheroder Weg 1b, D-38124 Braunschweig, Federal Republic of Germany

Date of deposit

21.09.1995

Accession Number

DSM No. 10260

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable) This information is continued on an additional sheet

In respect of those designations in which a European and/or Australian patent is sought, during the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71).

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., 'Accession Number of Deposit')

For receiving Office use only

This sheet was received with the international application

Authorized officer

*Anne-Søthe Henriksen*

For International Bureau use only

This sheet was received by the International Bureau on:

Authorized officer

**CLAIMS**

1. A method of detecting a biologically active substance affecting intracellular processes, the method comprising

(a) culturing a cell containing a DNA sequence coding for

5 (i) a green fluorescent protein (GFP) having a protein kinase recognition site, or

(ii) a green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or

10 (iii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and an enzyme recognition site or a binding domain for a second messenger

under conditions permitting expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

(c) incubating the cell with a sample suspected of containing a biologically active substance affecting intracellular processes, and

15 (d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), such change being indicative of the presence of a biologically active substance in said sample.

2. A method of detecting a biologically active substance affecting intracellular processes according to claim 1, the method comprising

20 (a) culturing a cell containing a DNA sequence coding for

(i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or

5 (ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site

under conditions permitting expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

(c) incubating the cell with a sample suspected of containing a biologically active substance affecting intracellular processes, and

10 (d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), such change being indicative of the presence of a biologically active substance in said sample.

3. A method according to any one of the preceding claims, wherein the cell is a eukaryotic cell.

15 4. A method according to any one of the preceding claims, wherein the cell is a yeast cell or a mammalian cell.

5. A method according to any one of the preceding claims, wherein the binding domain is a receptor.

6. A method according to any one of the preceding claims, wherein the binding domain  
20 is a cyclic AMP receptor or a part thereof capable of binding cyclic AMP.

7. A method according to any one of the preceding claims, wherein the enzyme recognition site is a protein kinase recognition site.

8. A method according to any one of the preceding claims, wherein the protein kinase recognition site is selected from the group consisting of protein kinase A, protein kinase C, the insulin receptor, and the Src kinase.
9. A method according to any one of the preceding claims, wherein the gene encoding GFP is derived from *Aequorea victoria*.
10. A method of characterizing the biological activity of a substance with biological activity, the method comprising
  - (a) culturing a cell containing a DNA sequence coding for
    - (i) a green fluorescent protein having a protein kinase recognition site, or
    - (ii) a green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or
    - (iii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site
  - 15 under conditions permitting expression of the DNA sequence,
  - (b) measuring the fluorescence of the cell,
  - (c) incubating the cell with a sample of a biologically active substance affecting intracellular processes, and
  - (d) measuring the fluorescence produced by the incubated cell and determining any 20 change in the fluorescence compared to the fluorescence measured in step (b), said change being characteristic of the biological activity of the biologically active substance in said sample.

11. A method of characterizing the biological activity of a substance with biological activity according to claim 10, the method comprising

(a) culturing a cell containing a DNA sequence coding for

5 (i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or

(ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site

under conditions permitting expression of the DNA sequence,

10 (b) measuring the fluorescence of the cell,

(c) incubating the cell with a sample of a biologically active substance affecting intracellular processes, and

15 (d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), said change being characteristic of the biological activity of the biologically active substance in said sample.

12. A method according to any one of claims 10 or 11, wherein the cell is a eukaryotic cell.

13. A method according to any one of claim 10, 11 or 12, wherein the cell is a yeast cell 20 or a mammalian cell.

14. A method according to any one of claims 10, 11, 12 or 13, wherein the binding domain is a receptor.

15. A method according to any one of claims 10, 11, 12, 13 or 14, wherein the binding domain is a cyclic AMP receptor or a part thereof capable of binding cyclic AMP.
16. A method according to any one of claims 10, 11, 12, 13, 14 or 15 wherein the enzyme recognition site is a protein kinase recognition site.
- 5 17. A method according to any one of claims 10, 11, 12, 13, 14, 15 or 16, wherein the protein kinase recognition site is selected from the group consisting of protein kinase A, protein kinase C, the insulin receptor, and the Src kinase.
18. A method according to any one of claims 10, 11, 12, 13, 14, 15, 16, or 17 wherein the gene encoding GFP is derived from *Aequorea victoria*.
- 10 19. A cell containing a DNA sequence coding for
  - (i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or
  - (ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP
- 15 and a binding domain of a second messenger or an enzyme recognition site, and capable of expressing said DNA sequence.
20. A cell according to claim 19, which is a eukaryotic cell.
21. A cell according to any one of claims 19 or 20, which is yeast cell or a mammalian cell.
- 20 22. A cell according to any one of claims 19, 20 or 21 wherein the binding domain is a receptor.

23. A cell according to any one of claims 19, 20, 21 or 22, wherein the binding domain is a cyclic AMP receptor or a part thereof capable of binding cyclic AMP.

24. A cell according to any one of claims 19, 20, 21, 22 or 23 wherein the enzyme recognition site is a protein kinase recognition site.

5 25. A cell according to any one of claims 19, 20, 21, 22, 23 or 24, wherein the protein kinase recognition site is selected from the group consisting of protein kinase A, protein kinase C, the insulin receptor, and the Src kinase.

26. A cell according to any one of claims 19, 20, 21, 23, 24 or 25 wherein the gene encoding GFP is derived from *Aequorea victoria*.

10 27. A DNA construct comprising a DNA sequence coding for

(i) green fluorescent protein wherein one or more amino acids have been substituted, inserted or deleted to provide a binding domain of a second messenger or an enzyme recognition site, or

15 (ii) a hybrid polypeptide of green fluorescent protein (GFP) or a modified GFP and a binding domain of a second messenger or an enzyme recognition site.

28. A DNA construct according to claim 27, wherein the binding domain is a receptor.

29. A cell according to any one of claims 27 or 28, wherein the binding domain is a cyclic AMP receptor or a part thereof capable of binding cyclic AMP.

30. A DNA construct according to any one of claims 27, 28 or 29 wherein the enzyme 20 recognition site is a protein kinase recognition site.

31. A DNA construct according to any one of claims 27, 28, 29 or 30, wherein the protein kinase recognition site is selected from the group consisting of protein kinase A, protein kinase C, the insulin receptor, and the Src kinase.

32. A DNA construct according to any one of claims 27, 28, 29, 30 or 31 wherein the 5 gene encoding GFP is derived from *Aequorea victoria*.

33. A method of detecting a biologically active substance affecting intracellular processes according to claim 1, the method comprising

(a) culturing a cell containing a DNA sequence coding for wild-type green fluorescent protein (GFP) having a protein kinase recognition site under conditions permitting 10 expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

(c) incubating the cell with a sample suspected of containing a biologically active substance affecting intracellular processes, and

(d) measuring the fluorescence produced by the incubated cell and determining any 15 change in the fluorescence compared to the fluorescence measured in step (b), such change being indicative of the presence of a biologically active substance in said sample.

34. A method according to the preceding claim, wherein the cell is a eukaryotic cell.

35. A method according to any one of claims 33 or 34, wherein the cell is a yeast cell or a mammalian cell.

20 36. A method according to any one of claims 33, 34 or 35 wherein the protein kinase recognition site is selected from the group consisting of protein kinase A, protein kinase C, the insulin receptor, and the Src kinase.

37. A method according to any one of claims 33, 34, 35 or 36 wherein the protein kinase recognition site is a protein kinase A recognition site.

38. A method according to any one of claims 33, 34, 35, 36 or 37, wherein the DNA sequence encoding GFP is derived from *Aequorea victoria*.

5 39. A method according to any one of claims 33, 34, 35, 36, 37 or 38, wherein the DNA sequence is identical to the nucleotide sequence of Fig. 4a or any functional analogue thereof.

40. A method of characterizing the biological activity of a substance with biological activity according to claim 10, the method comprising

10 (a) culturing a cell containing a DNA sequence coding for a wild-type green fluorescent protein having a protein kinase recognition site under conditions permitting expression of the DNA sequence,

(b) measuring the fluorescence of the cell,

15 (c) incubating the cell with a sample of a biologically active substance affecting intracellular processes, and

(d) measuring the fluorescence produced by the incubated cell and determining any change in the fluorescence compared to the fluorescence measured in step (b), said change being characteristic of the biological activity of the biologically active substance in said sample.

20 41. A method according to claim 40, wherein the cell is a eukaryotic cell.

42. A method according to any one of claims 40 or 41, wherein the cell is a yeast cell or a mammalian cell.

43. A method according to any one of claims 40, 41 or 42, wherein the protein kinase recognition site is a protein kinase A recognition site.

44. A method according to any one of claims 40, 41, 42 or 43, wherein the DNA sequence encoding GFP is derived from *Aequorea victoria*.

5 45. A method according to any one of claims 40, 41, 42, 43 or 44, wherein the DNA sequence is the nucleotide sequence of Fig. 4a or any functional analogue thereof.

46. A DNA construct containing the nucleotide sequence of Fig. 4a.

47. A transformation vector containing the nucleotide sequence of Fig. 4a.

48. A transformed cell containing the DNA construct of claim 46.

10 49. A transformed cell according to the preceding claim, characterised by being a mammalian cell.

50. The transformed *E. coli* having the deposition No. DSM 10260.

51. An *in vitro* assay for measuring protein kinase A activity, wherein purified wild-type GFP is added to a biological sample, preferably a cell extract, and any change in 15 fluorescence of the GFP is recorded.

52. An *in vitro* assay for monitoring cAMP levels in a sample, wherein wild-type GFP and tetrameric PKA having two regulatory and two catalytic subunits are added to a sample, preferably a cell extract, and any change in fluorescence is recorded.

1/5




Fig. 1

2/5





Fig. 2

3/5

Figure 3

4/5

Nucleotide sequence (764bp) of GFP  
(Hind3-EcoRI fragment)

AAGCTTTATGAGTAAAGGAGAAGAACCTTTCACTGGAGTT  
GTCCCAATTCTTGTGAATTAGATGGCGATGTTAATGGGC  
AAAAAATTCTCTGTTAGTGGAGAGGGTGAAGGTGATGCAAC  
ATACGGAAAACCTTACCCCTAAATTATTTGCACTACTGGG  
AAGCTACCTGTTCCATGGCCAACGCTTGTCACTACTTTCT  
CTTATGGTGTCAATGCTTTCAAGATAACCCAGATCATAT  
GAAACAGGCATGACTTTCAAGAGTGCCTGCCATGCCGAAGGT  
TATGTACAGGAAAGAACTATATTACAAAGATGACGGGA  
ACTACAAGACACGTGCTGAAGTCAAGTTGAAGGTGATAC  
CCTTGTAAATAGAACATCGAGTTAAAGGTATTGATTTAAA  
GAAGATGGAACACATTCTTGGACACAAAATGGAATACAAC  
ATAACTCACATAATGTATACATCATGGCAGACAAACAAA  
GAATGGCATCAAAGTTAACTTCAAAATTAGACACAAACATT  
AAAGATGGAAGCGTCAATTAGCAGACCATTATCAACAAA  
ATACTCCAATTGGCGATGGCCCTGTCCTTTACCAAGACAA  
CCATTACCTGTCCACGCAATCTGCCCTTCAAAAGATCCC  
AACGAAAAGAGAGATCACATGATCCTTCTTGAGTTGTAA  
CAGCTGCTGGATTACACATGGCATGGATGAACTATACAA  
ATAAAATGTCCAGACTTCCAATTGACACTAAAGGGATCCGA  
ATTC

Fig. 4a

5/5

## Amino acid sequence:

Start codon ATG corresponds to position 8 in the nucleotide sequence above and stop codon TAA corresponds to position 722.

1/1	31/11
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt gaa tta gat ggc	
Met ser lys gly glu glu leu phe thr gly val val pro ile leu val glu leu asp gly	
61/21	91/31
gat gtt aat ggg caa aaa ttc tct gtt agt gga gag ggt gaa ggt gat gca aca tac gga	
asp val asn gly gin lys phe ser val ser gly glu gly glu gly asp ala thr tyr gly	
181/61	211/71
aaa ctt acc ctt aaa ttt att tgc act act ggg aag cta cct gtt cca tgg cca acg ctt	
lys leu thr leu lys phe ile cys thr thr gly lys leu pro val pro trp pro thr leu	
121/41	151/51
gtc act act ttc tct tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cag	
val thr thr phe ser tyr gly val gin cys phe ser arg tyr pro asp his met lys gin	
241/81	271/91
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga act ata ttt tac	
his asp phe lys ser ala met pro glu gly tyr val gin glu arg thr ile phe tyr	
301/101	331/111
aaa gat gac ggg aac tac aag aca cgt gct gaa gtc aag ttt gaa ggt gat acc ctt gtt	
lys asp asp gly asn tyr lys thr arg ala glu val lys phe glu gly asp thr leu val	
361/121	391/131
aat aga atc gag tta aaa ggt att gat ttt aaa gaa gat gga aac att ctt gga cac aaa	
asn arg ile glu leu lys gly ile asp phe lys glu asp gly asn ile leu gly his lys	
421/141	451/151
atg gaa tac aac tat aac tca cat aat gta tac atc atg gca gac aaa cca aag aat ggc	
met glu tyr asn tyr asn ser his asn val tyr ile met ala asp lys pro lys asn gly	
481/161	511/171
atc aaa gtt aac ttc aaa att aga cac aac att aaa gat gga agc gtt caa tta gca gac	
ile lys val asn phe lys ile arg his asn ile lys asp gly ser val gin leu ala asp	
541/181	571/191
cat tat caa caa aat act cca att ggc gat ggc cct gtc ctt tta cca gac aac cat tac	
his tyr gin gln asn thr pro ile gly asp gly pro val leu leu pro asp asn his tyr	
601/201	631/211
ctg tcc acg caa tct gcc ctt tcc aaa gat ccc aac gaa aag aga gat cac atg atc ctt	
leu ser thr gln ser ala leu ser lys asp pro asn glu lys arg asp his met ile leu	
661/221	691/231
ctt gag ttt gta aca gct gct ggg att aca cat ggc atg gat gaa cta tac aaa taa	
leu glu phe val thr ala ala gly ile thr his gly met asp glu leu tyr lys OCH	

Fig. 4b

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00052

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12Q 1/00, C07K 14/435  
 According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12Q, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, MEDLINE, CA, USPATFULL, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9521191 A1 (WARD, WILLIAM ET AL), 10 August 1995 (10.08.95), see page 17 --	1-52
P,X	WO 9507463 A1 (THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK), 16 March 1995 (16.03.95) --	1-52
A	US 4220450 A (MAGGIO), 2 Sept 1980 (02.09.80) --	1-52
A	SCIENCE, Volume 263, February 1994, MARTIN CHALFIE ET AL, "GREEN FLUORESCENT PROTEIN AS A MARKER FOR GENE EXPRESSION" page 802 -- -----	1-52

Further documents are listed in the continuation of Box C.

See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

07 -05- 1996

3 May 1996

Name and mailing address of the ISA/  
 Swedish Patent Office  
 Box 5055, S-102 42 STOCKHOLM  
 Facsimile No. + 46 8 666 02 86

Authorized officer

Carolina Gomez  
 Telephone No. + 46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

01/04/96

International application No.	
PCT/DK 96/00052	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 9521191	10/08/95	NONE		
WO-A1- 9507463	16/03/95	NONE		
US-A- 4220450	02/09/80	DE-A- 2913549	18/10/79	
		FR-A,B- 2422165	02/11/79	
		GB-A,B- 2018424	17/10/79	
		JP-C- 1491117	07/04/89	
		JP-A- 54151894	29/11/79	
		JP-B- 63037347	25/07/88	
		US-A- 4277437	07/07/81	